Reading view
Chain of Evidence: Pixel-Level Visual Attribution for Iterative Retrieval-Augmented Generation
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial
Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01165-8
In this phase 2 trial, Perez et al. reported the safety of the vitamin D receptor agonist paricalcitol with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma and the pharmacodynamic effects of paricalcitol in fibroblasts and immune cells.From Concept to Practice: an Automated LLM-aided UVM Machine for RTL Verification
SkillX: Automatically Constructing Skill Knowledge Bases for Agents
ForestPrune: High-ratio Visual Token Compression for Video Multimodal Large Language Models via Spatial-Temporal Forest Modeling
Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma
Nature Cancer, Published online: 25 March 2026; doi:10.1038/s43018-026-01136-z
Czernilofsky et al. identified factors that reprogram stromal cells into an inflammatory, dysfunctional state, leading to the structural disorganization of lymph nodes in B cell lymphoma at single-cell and spatial resolutions.TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation
Oncogene, Published online: 24 March 2026; doi:10.1038/s41388-026-03728-6
TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylationArtificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.
ABSTRACT
Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.
PMID:41867453 | PMC:PMC13005593 | DOI:10.2147/JIR.S581764
Direct conversion from alkenes to alkynes
Nature, Published online: 16 March 2026; doi:10.1038/s41586-026-10372-3
Direct conversion from alkenes to alkynes